DOCSLIB.ORG

User's Manual for the SABE Databases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
User's Manual for the SABE Databases User’s Manual for the SABE Databases Washington, D.C. September 2004 The user’s manual for the SABE survey databases was prepared by the SABE regional coordination team of the Pan American Health Organization, Washington, DC, August 2004. International teams responsible for the survey in each of the seven cities provided technical support for the preparation and review of this document. Comments, questions, or requests for information can be directed to Martha Peláez at [email protected] 2 TABLE OF CONTENTS INTRODUCTION ………………………………………………………………………………….…… 4 PRINCIPAL SABE SURVEY RESEARCHERS………………………………………………..……...…6 DESIGN OF THE SAMPLE….……………………………………………………………...…...7 DIRECT, PROXY, AND ASSISTED INTERVIEWS ………..…………………………………..….........15 SECTION A: GENERAL DATA ………………………………………………………………………16. Identification of the Gender of the Interviewee A3 Classification and Code: Birthplace A11a Religion A12 Ethnic Group A13 History of Relationships and Marital Status SECTION B: COGNITIVE STATUS ……………………………….………………….……………….20 Mini Mental State Examination (MMSE) Pfeffer SECTION C: HEALTH STATUS.…………………………………………………………..………….21 C6c Organ(s) or Part(s) of the Body where Cancer Began C17 Geriatric Oral Health Assessment Index (GOHAI) (C17-C17K) C21a-o Yesavage Geriatric Depression Scale C22a-y Other Variables: Nutritional Evaluation C24 Smoking C28h Illnesses during Childhood SECTION D: FUNCTIONAL STATUS ………….………….……………………………………….....28 SECTION E: MEDICINES……………………………………………………………………………..29 E-2 Medicines Codes SECTION F: USE AND ACCESSIBILITY OF SERVICES ………………………………………..........35 F1 Type of Health Insurance SECTION G: FAMILY AND SOCIAL SUPPORT NETWORK………………………………………...…36 SECTION H: WORK HISTORY AND SOURCES OF INCOME ………………………………………...36 H9 / H16 Occupation or Type of Work H10 Most Important Activities or Tasks of Primary Job H11 Type of Activity H17 Reasons for Changing Jobs H20 Work-related Health Problems SECTIONS K AND L: ANTHROPOMETRY AND TESTS OF FUNCTIONALITY…………………………38 INTER-AMERICAN DEVELOPMENT BANK MODULES………………………………………………..39 SELECTED BIBLIOGRAPHICAL REFERENCES………………………………...............………...….41 3 INTRODUCTION Objectives of the Survey on Health, Welfare, and Aging in Latin America and the Caribbean (SABE) The protocol of the SABE survey,1 which is included in this CD, should be reviewed in order to understand both the general and particular objectives of the survey as well as the proposed methodology for the design of the sample. The document entitled “Survey on Health and Well-being of Elders: Regional Findings” should also be consulted.2 That document is also included in the information package that accompanies the databases. The SABE survey was designed to produce information that enables researchers to achieve, at a minimum, the following goals: a) Describe the health conditions of older adults (age 60 and older) with regard to chronic and acute diseases, disability, and physical and mental impairment in seven Latin American cities (Buenos Aires, Santiago, São Paulo, Montevideo, Mexico, Havana, and Bridgetown). It is important to emphasize that the findings represent the prevalence rates of those illnesses as reported by the interviewees, except in the countries where screening tests were carried out. Such was the case for Mexico City, where blood samples were taken after fasting to detect diabetes. b) Evaluate the extent to which older adults use and have access to health care services, including services that are outside the formal system (local healers, traditional medicine), as well as the conditions under which people seek and obtain these services. The countries included in the SABE study differ dramatically with regard to the organization and administration of their health facilities, and their health systems have gone through major changes in recent years. Consequently, it is important for the researchers to familiarize themselves with the health systems of each country by exchanging information with the principal researchers in each locality. c) Evaluate the proportional contribution by principal sources of support—relatives and family networks, public assistance, and private resources (income, assets)—towards meeting the health-related needs of older adults, Given the recent reorganization of pension and social welfare systems, the countries in this survey represent a unique opportunity to study the differences between and within social contexts in terms of the availability of public and private health programs and plans, as well as the extent to which those programs and plans influence the health status of older adults and their access to and use of health care services. Before making any inferences based on SABE data, it is important to have a good understanding of the social context and the supply of services in each locality. d) Evaluate access to health insurance offered by private organizations, governmental institutions, and mixed systems, as well as the extent to which that insurance is actually used. In several countries, such as Barbados and Brazil, there are explicit guarantees to universal access to the health system. In others, the lack of such explicit guarantees to insurance constrains access to services. It is important to underline the need to complement any analysis of the data with information on the types of coverage in each locality during the survey period (1999-2000). e) Analyze the differentials in the self-evaluation of health conditions, access to health care, and sources of support with regard to socioeconomic group, gender, and birth cohort. 1 Alberto Palloni (1998). Protocol of the Multicenter Survey on Health, Welfare and Aging. CD-ROM PAHO/SABE-2000. 2 Peláez, M., and A. Palloni (2004). Survey on Health and Well-being of Elders: Regional Findings. CD-ROM PAHO/SABE-2000. 4 f) Evaluate the relationships between strategic factors—health-related behavior, occupational background, socioeconomic status, gender, and cohort—in health conditions, according to the health evaluation at the time of the survey. g) Carry out comparative analyses in countries that share similar characteristics but that differ with regard to such factors as the role of family support, public assistance, access to health services, and health-related behavior and exposure to risk. Language The surveys were conducted in the official language of each country: - Spanish in Buenos Aires (Argentina), Mexico City (Mexico), Havana (Cuba), and Formatted: Spanish Montevideo (Uruguay); (Spain-Traditional Sort) - English in Bridgetown (Barbados); - Portuguese in São Paulo (Brazil). The original languages were maintained during processing of the databases. However, in order to assist users, databases in the STATA format included (in the field labeled “Notes”) translations of the name of the variable in the three official languages of SABE. As a result, users will have access to the seven databases in the three languages used in the survey. Dates of the Field Work The Santiago team began field work at the end of 1999 and finished at the start of 2000, while the teams for the remaining countries began in the first quarter of 2000 and finished in the second half of 2000. How to Cite SABE Data In accordance with international standards, we recommend citing the SABE database as follows: Peláez, Martha; Palloni, Alberto; Albala, Cecilia; Alfonso, Juan C; Ham-Chande, Roberto; Hennis, Anselm; Lebrao, Maria Lucia; León-Diaz, Esther; Pantelides, Edith; Prats, Omar. SABE - Survey on Health, Welfare, and Aging, 2000 [electronic file]: Pan American Health Organization (PAHO/WHO) [producer and distributor], 2004. 5 PRINCIPAL SABE SURVEY RESEARCHERS The names and electronic addresses of SABE researchers are listed below. Regional Coordination: Martha Peláez, Ph.D. ([email protected]) Pan American Health Organization Alberto Palloni, Ph.D. ([email protected]) University of Wisconsin-Madison Principal Researchers in Each Locality: Bridgetown, Barbados: Anselm Hennis, MD ([email protected]) - Chronic Disease Research Centre, School of Clinical Medicine and Research - University of the West Indies Buenos Aires, Argentina: Edith Pantelides, Ph.D. ([email protected]) - Centro de Estudios de Población/CENEP (Center for Population Studies) Havana, Cuba: Juan Carlos Alfonso, Esther María León Díaz ([email protected]; [email protected]) - Centro de Estudios de Población y Desarrollo (CEPDE), Oficina Nacional de Estadística (Center of Population and Development Studies, National Statistics Office) DF Mexico, Mexico: Roberto Ham-Chande, Ph.D. ([email protected]) - El Colegio de la Frontera Norte, Tijuana, Baja California and Luis Miguel Gutierrez, MD ([email protected]) - Instituto Nacional de la Nutrición "Salvador Zubirán," (“Salvador Zubirán” National Nutrition Institute), México, D.F., and Yolanda Palma, INSAD en México, DF ([email protected]). Montevideo, Uruguay: Omar Prats, MD ([email protected]) - Comisión Salud Cardiovascular y Universidad de Uruguay. (Commission on Cardiovascular Health, University of Uruguay) Santiago, Chile: Cecilia Albala, MD, MPH ([email protected]; [email protected]) - Instituto de Nutrición y Tecnología de los Alimentos (INTA), Universidad de Chile (Institute of Nutrition and Food Technology, University of Chile) and Pedro Paulo Marín, MD ([email protected]) - Pontificia Universidad Católica de Chile. São Paulo, Brazil: Maria Lucia Lebrao, MD ([email protected]), Ruy Laurenti - Faculdade de Saúde Pública, Universidade de São Paulo (Public Health Faculty, University of São Paulo). 6 DESIGN OF THE
Load more

Recommended publications
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Interventions for Cough in Cancer (Review)
    Interventions for cough in cancer (Review) Molassiotis A, Bailey C, Caress A, Brunton L, Smith J This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2010, Issue 9 http://www.thecochranelibrary.com Interventions for cough in cancer (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 DISCUSSION ..................................... 7 AUTHORS’CONCLUSIONS . 8 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 CHARACTERISTICSOFSTUDIES . 13 DATAANDANALYSES. 33 APPENDICES ..................................... 33 HISTORY....................................... 40 CONTRIBUTIONSOFAUTHORS . 41 DECLARATIONSOFINTEREST . 41 SOURCESOFSUPPORT . 41 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . .... 41 NOTES........................................ 41 Interventions for cough in cancer (Review) i Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Interventions for cough in cancer Alex Molassiotis1, Chris Bailey2, Ann Caress1, Lisa Brunton1, Jacky Smith3 1School of Nursing, Midwifery & Social Work, University of Manchester, Manchester, UK.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Elif Fatma Sen BW.Indd
    Use and Safety of Respiratory Medicines in Children E. F. Şen EEliflif FFatmaatma SSenen BBW.inddW.indd 1 003-01-113-01-11 115:175:17 The work presented in this thesis was conducted at the Department of Medical Informatics of the Erasmus University Medical Center, Rotterdam. The research reported in thesis was funded by the European Community’s 6th Framework Programme. Project number LSHB-CT-2005-005216: TEDDY: Task force in Europe for Drug Development for the Young. The contributions of the participating primary care physicians in the IPCI, Pedianet and IMS-DA project are greatly acknowledged. Financial support for printing this thesis was kindly provided by the department of Medical Informatics – Integrated Primary Care Information (IPCI) project of the Erasmus University Medi- cal Center; and by the J.E. Jurriaanse Stichting in Rotterdam. Cover: Optima Grafi sche Communicatie Printed by: Optima Grafi sche Communicatie Elif Fatma Şen Use and Safety of Respiratory medicines in Children ISBN: 978-94-6169-003-6 © E.F. Şen, Rotterdam, the Netherlands, 2011. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the holder of the copyright. EEliflif FFatmaatma SSenen BBW.inddW.indd 2 003-01-113-01-11 115:175:17 Use and Safety of Respiratory Medicines in Children Het gebruik en de bijwerkingen van respiratoire medicijnen in kinderen Proefschrift Ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnifi cus Prof.dr.
    [Show full text]
  • Laaketilasto07 2.Pdf
    Keskeisiä lukuja lääkkeiden myynnistä ja lääkekorvauksista vuonna 2007 Muutos vuodesta 2006 Lääkkeiden kokonaismyynti 2 500 milj. € 5,9 % avohoidon reseptilääkkeiden myynti (verollisin vähittäismyyntihinnoin) 1 817 milj. € 4,2 % avohoidon itsehoitolääkkeiden myynti (verollisin vähittäismyyntihinnoin) 275 milj. € 15,5 % sairaalamyynti (tukkuohjehinnoin) 408 milj. € 7,5 % Lääkkeistä maksetut korvaukset 1 142 milj. € 3,8 % peruskorvaukset 369 milj. € 0,6 % erityiskorvaukset 662 milj. € 6,8 % lisäkorvaukset 111 milj. € -2,3 % Key figures for medicine sales and their reimbursement in 2007 Change from 2006 Total sales of pharmaceuticals EUR 2,500 million 5.9% prescription medicines in outpatient care (at pharmacy prices with VAT) EUR 1,817 million 4.2% OTC medicines in outpatient care (at pharmacy prices with VAT) EUR 275 million 15.5% sales to hospitals (at wholesale prices) EUR 408 million 7.5% Reimbursement of medicine costs EUR 1,142 million 3.8% Basic Refunds EUR 369 million 0.6% Special Refunds EUR 662 million 6.8% Additional Refunds EUR 111 million -2.3% SUOMEN LÄÄKETILASTO FINNISH STATISTICS ON MEDICINES 2007 Lääkelaitos ja Kansaneläkelaitos National Agency for Medicines and Social Insurance Institution Helsinki 2008 LÄÄKELAITOS KANSANELÄKELAITOS NATIONAL AGENCY SOCIAL INSURANCE FOR MEDICINES INSTITUTION Lääketurvaosasto Tutkimusosasto Department of Safety Research Department and Drug Information Mannerheimintie 103b Nordenskiöldinkatu 12 P.O. Box 55 P.O. Box 450 FI-00301 Helsinki FI-00101 Helsinki Finland Finland Puh. (09) 473 341 Puh. 020 634 11 Tel. +358 9 473 341 Tel. +358 20 634 11 Telekopio (09) 473 34297 Telekopio 020 634 1700 Fax +358 9 473 34297 Fax +358 20 634 1700 ISSN 0786-2180 Kansi / Cover: Kari Piippo Edita Prima Oy Helsinki 2008 SISÄLLYS Kuvaluettelo .....................................................................................................................
    [Show full text]
  • 1554 Cough Suppressants Expectorants Mucolytics and Nasal Decongestants Chronic Obstructive Pulmonary Disease
    1554 Cough Suppressants Expectorants Mucolytics and Nasal Decongestants Chronic obstructive pulmonary disease. The value of mu- Profile Preparations colytic therapy in chronic obstructive pulmonary disease Clobutinol hydrochloride is a centrally acting cough suppressant Proprietary Preparations (details are given in Part 3) (COPD—p.1112) is controversial. Two studies have reported for non-productive cough (p.1547) that has been given orally in some improvements in lung function in patients with chronic doses of 40 to 80 mg three times daily; it has also been given by Multi-ingredient: Ital.: Localyn. bronchitis given carbocisteine for up to 6 months,1,2 but it ap- subcutaneous, intramuscular, or intravenous injection. However, peared to have no effect on the number of acute exacerbations.1 the EMEA has recommended for its withdrawal due to the risk However, later studies3,4 have reported reductions in the number of QT interval prolongation. Cloperastine (rINN) of acute exacerbations; the number of common colds was also Preparations Cloperastina; Clopérastine; Cloperastinum; HT-11. 1-{2-[(p- lower in the carbocisteine group in one of the studies.4 Carbo- Chloro-α-phenylbenzyl)oxy]ethyl}piperidine. cisteine may also produce some beneficial effects on sputum rhe- Proprietary Preparations (details are given in Part 3) ology.2,5 Arg.: Proking; Silomat†; Austria: Silomat†; Belg.: Silomat†; Braz.: Silo- Клоперастин mat†; Chile: Broncodual; Calfetos; Clobatos†; Cloval; Pulbronc Simple; Si- C H ClNO = 329.9. 1. Grillage M, Barnard-Jones K. Long-term oral carbocisteine ther- lomat†; Cz.: Silomat†; Fin.: Mixtus; Silomat†; Fr.: Silomat†; Ger.: Husten- 20 24 apy in patients with chronic bronchitis: a double blind trial with stiller†; Nullatuss†; Rofatuss†; Silomat†; stas-Hustenstiller N†; Tussed†; Gr.: CAS — 3703-76-2 (cloperastine); 132301-89-4 (levoclop- placebo control.
    [Show full text]
  • 2009 Nhamcs Micro-Data File Documentation Page 1
    2009 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 1 ABSTRACT This material provides documentation for users of the public use micro-data files of the 2009 National Hospital Ambulatory Medical Care Survey (NHAMCS). NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Surveys, which measure health care utilization across a variety of health care providers. There are two micro-data files produced from NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, “Description of the National Hospital Ambulatory Medical Care Survey,” includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file’s data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey. PAGE 2 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION SUMMARY OF CHANGES FOR 2009 The 2009 NHAMCS Emergency Department and Outpatient Department public use micro-data files are, for the most part, similar to the 2008 files, but there are some important changes. These are described in more detail below and reflect changes to the survey instrument, the Patient Record form. Emergency Departments 1. New or Modified Items a. In item 1, Patient Information, there is a new checkbox item “Arrival by Ambulance.” This replaces the 2008 item, “Mode of Arrival.” b.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]